🇺🇸 Nephrotrans in United States

162 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Anaemia — 30 reports (18.52%)
  2. General Physical Health Deterioration — 19 reports (11.73%)
  3. Blood Creatinine Increased — 17 reports (10.49%)
  4. Hyperkalaemia — 16 reports (9.88%)
  5. Dyspnoea — 15 reports (9.26%)
  6. Haemoglobin Decreased — 15 reports (9.26%)
  7. Asthenia — 14 reports (8.64%)
  8. Cardiac Failure — 12 reports (7.41%)
  9. Oedema — 12 reports (7.41%)
  10. Renal Failure — 12 reports (7.41%)

Source database →

Nephrotrans in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Nephrology approved in United States

Frequently asked questions

Is Nephrotrans approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Nephrotrans in United States?

University of Zurich is the originator. The local marketing authorisation holder may differ — check the official source linked above.